OCD Trial, Recruiting NCT04958096 Sponsor: Andrew Moses Lee, MD, PhD Condition: OCD
Back to Ocd

OCD Trial, Recruiting

NCT04958096
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to give your consent to participate in the study
  • You are between 22 and 75 years old
  • You have been diagnosed with OCD (Obsessive-Compulsive Disorder)
  • You have had OCD for at least 5 years
  • Your OCD is rated as severe or extreme (based on a specific symptom scale called the YBOCS, with a score of 28 or higher)
  • You have tried at least two SSRI medications (a common type of antidepressant), as well as a medication called clomipramine, and added-on antipsychotic medications, without enough improvement
  • You have tried a specific type of talking therapy for OCD (called cognitive behavioral therapy with exposure and response prevention) and it has not helped enough
  • You have tried a brain stimulation treatment called TMS for OCD (if it was available to you) and it did not help enough

Who may not be able to join:

  • Your main type of OCD involves hoarding as the primary problem
  • You have another serious mental health condition, such as a personality disorder, psychosis, bipolar disorder, or a substance misuse problem
  • You are pregnant
  • Your MRI scan shows something abnormal, or you have a brain or nervous system condition that may require an MRI in the future
  • You have a condition affecting memory or thinking ability, such as dementia
  • You are considered to be at immediate risk of suicide, or you have ever attempted suicide
  • You are unable to attend the required follow-up appointments during the study
  • You have a serious health condition that would make surgery more risky, such as a previous stroke, severely high blood pressure, severe diabetes, or a need for blood-thinning medication (other than aspirin)
  • You have a known allergy or sensitivity to the materials used in the device being studied, including titanium, polyurethane, silicone, or stainless steel
  • You have previously had brain surgery, including a similar type of brain stimulation surgery (deep brain stimulation) or surgery that removes brain tissue
  • You may not be eligible if the trial doctor feels that your individual circumstances significantly increase the risks or reduce the likely benefit of the treatment (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrew M Lee, MD, PhD, University of California, San Francisco

Phone: 415-502-5472

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Andrew Moses Lee, MD, PhD
Registry
ClinicalTrials.gov
Start date
1 August 2021
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) from 12 months to 24 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov